The Effects of Different Drugs on Isolated—Uterine Smooth Muscle in Pregnant Women

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-ORC-12002210

Enrollment

Unknown

Registered

2012-05-07

Start date

2011-04-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

isolated—uterine smooth muscle in pregnant women

Interventions

oxytocin:oxytocin

tropisetron:tropisetron

magnesium+ oxytocin:tropisetron

Hemabate+oxytocin:Hemabate+oxytocin

methergine:methergine

methergine+oxytocin:methergine+oxytocin

Dexmedetomidine:Dexmedetomidine

Dexmedetomidine+oxytocin:Dexmedetomidine+oxytocin

Control:salt water

Ondansetron:Ondansetron

Granisetron:Granisetron

metoclopramide+oxytocin:metoclopramide+oxytocin

Hemabate:Hemabate

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: ASA physical status I and II full-term parturients undergo-ing elective lower-segment cesarean delivery.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
amplitude;duration;delitescence;	—

Countries

China

Contacts

Public ContactXuemei LIN

lxm0301@gmail.com+86 13808038449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026